Cipla to market Roche’s antibody cocktail pan-India, first batch currently available

Roche India and Cipla announced that the first batch of the antibody cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June. In total they can potentially benefit 200,000 patients as each of the 100,000 packs that will be available in India offers treatment for two patients. Cipla will distribute the product by leveraging its strong distribution strengths across the country. The drug will be available through leading hospitals and COVID treatment centres. The Central Drugs Standards Control Organisation (CDSCO) had recently provided an Emergency Use Authorisation (EUA) for the antibody cocktail (Casirivimab and Imdevimab) in India. It has also received a EUA in the US and several EU countries.

“Roche is deeply committed to support the ongoing efforts to combat the COVID-19 pandemic, mitigate the deadly second wave and save lives. We are optimistic that the availability of Antibody Cocktail (Casirivimab and Imdevimab) in India can help in minimising hospitalisation, ease the burden on healthcare systems and play a key role in the treatment of high-risk patients before their condition worsens,” said V Simpson Emmanuel, MD and CEO, Roche Pharma India.

Commenting on the launch, Umang Vohra, MD & Global CEO Cipla said, “We are guided by our strong sense of responsibility to address unmet patient need and look forward to leveraging our solid marketing and distribution strengths in India to provide broader, equitable access to this innovative treatment option in the country”.

The antibody cocktail (Casirivimab and Imdevimab) is to be administered for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults and paediatric patients (12 years of age or older, weighing at least 40 kg) who are confirmed to be infected with SARS-COV2 and who are at high risk of developing severe COVID-19 disease and do not require oxygen. It has been shown to help these high-risk patients before their condition worsens, reducing the risk of hospitalisation and fatality by 70 per cent and shortening the duration of symptoms by four days.

In a statement, the company informed, “Each pack of Antibody Cocktail (Casirivimab and Imdevimab) contains one vial of Casirivimab and one vial of Imdevimab totaling 2400 mg of the antibody cocktail (one vial of Casirivimab (1200 mg) and one vial of Imdevimab (1200 mg)). Each pack can treat two patients as the dosage per patient is a combined dose of 1200 mg (600 mg of Casirivimab and 600 mg of Imdevimab) administered by intravenous infusion or subcutaneous route. The vials need to be stored at 2°C to 8°C. If opened for the first patients’ dose, a vial can be used for the second patients’ dose within 48 hours if stored at 2°C to 8°C. “

It further informed, “The price for each patient dose [a combined dose of 1200 mg (600 mg of Casirivimab and 600 mg of Imdevimab)] will be Rs 59,750 inclusive of all taxes. The maximum retail price for the multidose pack (each pack can treat two patients) is Rs 119,500 inclusive of all taxes.”

Antibody cocktail drug (Casirivimab and Imdevimab) will be available through Cipla’s distribution network across the country. Healthcare institutions, both private and public can place an enquiry by reaching out to their nearest Cipla distributor.

About the antibody cocktail

• The antibody cocktail (Casirivimab and Imdevimab) is a medical product that can be procured subject to a medical prescription by a registered medical practitioner

• Casirivimab and Imdevimab may only be administered in settings in which health care providers have immediate access to medications to treat an infusion reaction, such as anaphylaxis

• The intravenous administration takes about 20 to 30 minutes. For the subcutaneous route, four syringes of 2.5 ml (2 each of Casirivimab and Imdevimab) need to be administered concurrently at four different sites on the abdomen or thigh

• Patients should be monitored during the infusion and observed for least one hour after the completion of the infusion and 15–30 minutes after the subcutaneous injection